ZIOPHARM Oncology, Inc. (NASDAQ:ZIOP) Files An 8-K Shareholder Director NominationsItem 5.08
On July23, 2018, Ziopharm Oncology, Inc., or the Company, changed the date of the Company’s 2018 Annual Meeting of Stockholders, or the Annual Meeting, from September19, 2018 (as previously announced) to September18, 2018. The record date for the Annual Meeting, previously announced as July23, 2018, and the deadline for qualified stockholder proposals to be presented at the Annual Meeting and included in the Company’s proxy statement and form of proxy, previously announced as July20, 2018, have not changed. The Annual Meeting will be held at 10:00 a.m. Eastern time at the offices of Cooley LLP located at 1114 Avenue of the Americas, 46th Floor, New York, NY 10036-7798.
The disclosure in Item 5.08 is incorporated herein by reference thereto.
About ZIOPHARM Oncology, Inc. (NASDAQ:ZIOP)
ZIOPHARM Oncology, Inc. is a biopharmaceutical company. The Company is seeking to acquire, develop and commercialize, on its own or with partners, a portfolio of cancer therapies through synthetic immuno-oncology. Its clinical-stage product candidate, Ad-RTS-IL-12, is used with the oral activator veledimex. The Company’s Ad-RTS-IL-12 + veledimex has been evaluated in two Phase II studies, the first for the treatment of metastatic melanoma, and the second for the treatment of unresectable recurrent or metastatic breast cancer. It has initiated the Phase I study for malignant glioma. The Company has completed the Phase II monotherapy studies in melanoma and breast cancer using Ad-RTS-IL-12 + veledimex. It has initiated a Phase Ib/II study of Ad-RTS-hIL-12 + veledimex following chemotherapy for the treatment of patients with locally metastatic breast cancer. Its initial drug candidate being developed using the synthetic immuno-oncology platform is Ad-RTS-IL-12 + veledimex.